<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172379</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-E044-204</org_study_id>
    <nct_id>NCT01172379</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With &quot;Wearing Off&quot; Motor Fluctuations and &quot;On&quot; Period Dyskinesias</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With &quot;Wearing Off&quot; Motor Fluctuations and &quot;On&quot; Period Dyskinesias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability and efficacy of E2007 in&#xD;
      Parkinson's Disease patients who have &quot;wearing off&quot; motor fluctuations and &quot;on&quot; period&#xD;
      dyskenisias.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, double-blind, placebo-controlled, dose-ranging multicentre study with&#xD;
      parallel groups. Patients will be equally randomized to receive 0.5 mg, 1 mg or 2 mg of E2007&#xD;
      or matching placebo for 12 weeks (84 days) in addition to their stable antiparkinsonian&#xD;
      treatment. The study will involve two overnight in-patient stays. The first of these will be&#xD;
      for 2 nights and 3 days and the second will be for 1 night and 2 days. The remainder of the&#xD;
      study will be conducted on an outpatient basis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy assessments: Parkinsonian symptomology will be recorded on an out-patient basis using patient diary cards (indicating &quot;on&quot; and &quot;off&quot; periods, sleep and dyskinesias).</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment>2</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2007</intervention_name>
    <description>Experimental 1 Drug: E2007&#xD;
0.5 mg 1 tablet per day</description>
    <arm_group_label>Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2007</intervention_name>
    <description>Experimental 2 Drug: E2007&#xD;
1.0 mg 1 tablet per day</description>
    <arm_group_label>Experimental 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2007</intervention_name>
    <description>Drug: E2007&#xD;
2.0 mg 1 tablet per day</description>
    <arm_group_label>Experimental 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Placebo 1 tablet per day</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients with idiopathic PD fulfilling the Queen Square Brain Bank&#xD;
             diagnostic criteria, with good response to levodopa.&#xD;
&#xD;
          2. Patients must be aged 30-75 inclusive. Patients aged between 76-80 (inclusive) may be&#xD;
             enrolled with the prior agreement of the Study Medical Monitor.&#xD;
&#xD;
          3. Patients must have motor fluctuations of the wearing &quot;off&quot; type with the presence of&#xD;
             at least two and half hours of &quot;off&quot; time during the waking day and at least 90&#xD;
             minutes of &quot;off&quot; time during the eight hour period following the morning dose of&#xD;
             levodopa each per day as evidenced by history at Screening and confirmed by diary data&#xD;
             collected between Screening and Baseline.&#xD;
&#xD;
          4. Patients must have clinically relevant dyskinesias during the &quot;on&quot; period following&#xD;
             each morning dose of his/her current medication.&#xD;
&#xD;
          5. Patients must rate between II-IV on the Hoehn and Yahr scale when in an &quot;off&quot; state.&#xD;
&#xD;
          6. Patients must be taking levodopa at least three times daily.&#xD;
&#xD;
          7. Patients must have been on a fixed dose of any treatments for PD for at least 4 weeks&#xD;
             prior to the Baseline Visit.&#xD;
&#xD;
          8. In the Investigator's opinion patients must be able to distinguish their own motor&#xD;
             states and the absence or presence of dyskinesias.&#xD;
&#xD;
          9. Patients must be capable of giving full written informed consent.&#xD;
&#xD;
         10. In the Investigator's opinion patients must be of capable of completing patient diary&#xD;
             cards according to instructions.&#xD;
&#xD;
         11. In the Investigator's opinion patients who are good candidates and able to complete&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women.&#xD;
&#xD;
          2. Women of child-bearing potential unless infertile (including surgically sterile) or&#xD;
             practicing effective contraception (e.g., abstinence, IUD or barrier method plus&#xD;
             hormonal method). These patients must have a negative serum B-HCG test at the Initial&#xD;
             Screening Visit and a negative urine pregnancy test at the Baseline Visit. These&#xD;
             patients must also be willing to remain on their current form of contraception for the&#xD;
             duration of the study. Postmenopausal women may be recruited but must be amenorrhoeic&#xD;
             for at least 1 year to be considered of non-child bearing potential.&#xD;
&#xD;
          3. Fertile men not willing to use reliable contraception and fertile men with partners&#xD;
             not willing to use reliable contraception.&#xD;
&#xD;
          4. Patients with a past or present history of drug or alcohol abuse.&#xD;
&#xD;
          5. Patients with a past (within one year) or present history of psychotic symptoms&#xD;
             requiring antipsychotic treatment. Patients may be taking anti-depressant medication,&#xD;
             however, the dose must be stable for 8 weeks prior to the Baseline Visit.&#xD;
&#xD;
          6. Patients with unstable abnormalities of the hepatic, renal, cardiovascular,&#xD;
             respiratory, gastrointestinal, haematological, endocrine or metabolic systems which&#xD;
             might complicate assessment of the tolerability of the study medication.&#xD;
&#xD;
          7. Patients with significantly elevated liver enzymes (abnormal bilirubin or seum&#xD;
             transaminase levels of more than 1.5 times the upper normal limit).&#xD;
&#xD;
          8. Patients currently receiving treatment with medication that could significantly&#xD;
             interfere with gastric absorption.&#xD;
&#xD;
          9. Patients with current or prior treatment (within 4 weeks prior to the Baseline Visit)&#xD;
             with medication known to induce the enzyme cytochrome P450 3A4 including but not&#xD;
             limited to: carbamazepine; dexamethasone; ethosuximide; phenobarbital; phenytoin;&#xD;
             primidone; rifabutin; rifampacin; and St. John's Wort.&#xD;
&#xD;
         10. Current or prior treatment (within 4 weeks prior to Baseline Visit) with methyldopa,&#xD;
             budipine, reserpine or intermittent use of liquid forms of levodopa or apomorphine.&#xD;
&#xD;
         11. Patients with previous stereotactic surgery (e.g., pallidotomy) for Parkinson's&#xD;
             disease.&#xD;
&#xD;
         12. Patients receiving deep brain stimulation.&#xD;
&#xD;
         13. Patients who have received an investigational product within 12 weeks prior to&#xD;
             Baseline Visit or patients that have participated in a previous study with E2007.&#xD;
&#xD;
         14. Patients with clinically significant cognitive impairment (MMSE ; 24 and/or fulfilling&#xD;
             DSM IV criteria for dementia due to Parkinson's disease).&#xD;
&#xD;
         15. Patients with conditions affecting the peripheral or central sensory system unless&#xD;
             related to Parkinson's disease (mild sensory or pain syndromes limited to off periods)&#xD;
             that could interfere with the evaluation of any such symptoms caused by the study&#xD;
             drug.&#xD;
&#xD;
         16. Patients with any condition that would make the patient, in the opinion of the&#xD;
             Investigator, unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Webster</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic of Neurology, Faculty Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Neurology Practise</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Regional Hospital Pardubice</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Faculty of Medicine Charles University</name>
      <address>
        <city>Prague</city>
        <zip>120 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology - Second Faculty of Medicine Charles University</name>
      <address>
        <city>Prague</city>
        <zip>84 - 150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre D'Investigation Clinique Pavillon Riser - Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Competence Network Germany Dept. of Neurology - Philipps-University Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hesse</state>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humboldt Universit?t Charite Neurologische Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Friedrich-Wilhelms- Univerit?t Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>D-53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralkrankenhaus Reinkenheide Neurologische Klinik</name>
      <address>
        <city>Bremerhaven</city>
        <zip>D-27574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Heinrich-Heine- Universit?t</name>
      <address>
        <city>D?sseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis</name>
      <address>
        <city>Erbach</city>
        <zip>D-64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Georg-August- Universit?t</name>
      <address>
        <city>G?ttingen</city>
        <zip>D-37099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit?tskrankenh aus Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Hanau</name>
      <address>
        <city>Hanau</city>
        <zip>D-63450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit?tsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit?tsklinikum</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>D-66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus-Elena-Kli nik</name>
      <address>
        <city>Kassel</city>
        <zip>D-34126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit?tsklinikum Rostock Klinik f?r Neurologie</name>
      <address>
        <city>Rostock</city>
        <zip>D-18147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reparto di Neurologia - Ospedale Misericordia</name>
      <address>
        <city>Grosseto</city>
        <zip>171 - 58100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit? di Napoli Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>5 - 80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unit? Operativa Parkinson e Disordini del Movimento</name>
      <address>
        <city>Pavia</city>
        <zip>6 - 27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Neuromed SRL Neurologia</name>
      <address>
        <city>Pozzilli</city>
        <zip>18 - 86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III Clinica Neurologica</name>
      <address>
        <city>Roma</city>
        <zip>30 - 00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Militzary Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Neurology</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology</name>
      <address>
        <city>Belrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>119 - 08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>25-29 08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <zip>25-27 - 08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>July 26, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <last_update_submitted>August 21, 2014</last_update_submitted>
  <last_update_submitted_qc>August 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <responsible_party>
    <name_title>Eisai Medical Services</name_title>
    <organization>Eisai Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

